Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05340647
Other study ID # 415116
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date April 22, 2022
Est. completion date June 2028

Study information

Verified date November 2022
Source Oslo University Hospital
Contact Olav Kristianslund, MD PhD
Phone +4722118545
Email olakri@ous-hf.no
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

NorMIGS is a non-randomized clinical study of intraocular pressure lowering effect and complications after Preserflo microshunt implantation versus other types of glaucoma surgery. The study is conducted in the Department of Ophthalmology, Oslo University Hospital, Norway.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date June 2028
Est. primary completion date December 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients must be 18 years or older at the time of signing the informed consent form. There is no upper age limit. - Scheduled for implantation of Preserflo microshunt, trabeculectomy or other types of MIGS - Ability to cooperate fairly well during the examinations - Willing to participate in the study and capable of providing informed consent Exclusion Criteria: - High intraocular pressure due to increased episcleral venous pressure, hemorrhagic glaucoma, traumatic glaucoma or uveitis glaucoma

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Preserflo microshunt
Implantation of Preserflo microshunt (Santen) to lower intraocular pressure
Trabeculectomy
Trabeculectomy surgery to lower intraocular pressure
Other MIGS
Other MIGS than Preserflo microshunt (e.g., XEN gel stent, iStent inject) to lower intraocular pressure

Locations

Country Name City State
Norway Department of Ophthalmology, Oslo University Hospital Oslo

Sponsors (1)

Lead Sponsor Collaborator
Oslo University Hospital

Country where clinical trial is conducted

Norway, 

Outcome

Type Measure Description Time frame Safety issue
Primary Intraocular pressure Measured by tonometry 8 weeks after surgery
Secondary Intraocular pressure Measured by tonometry 6 months after surgery
Secondary Intraocular pressure Measured by tonometry 2 years after surgery
Secondary Intraocular pressure Measured by tonometry 5 years after surgery
Secondary Visual outcome Measure uncorrected and corrected distance visual acuity using visual acuity chart 8 weeks after surgery
Secondary Visual outcome Measure uncorrected and corrected distance visual acuity using visual acuity chart 6 months after surgery
Secondary Visual outcome Measure uncorrected and corrected distance visual acuity using visual acuity chart 2 years after surgery
Secondary Visual outcome Measure uncorrected and corrected distance visual acuity using visual acuity chart 5 years after surgery
Secondary Intraocular inflammation Measured by laser flare meter 4 weeks after surgery
Secondary Intraocular inflammation Measured by laser flare meter 6 months after surgery
Secondary Central macular thickness (CMT) Measure CMT (in um) on optical coherence tomography (OCT) 4 weeks after surgery
Secondary Central macular thickness (CMT) Measure CMT (in um) on optical coherence tomography (OCT) 6 months after surgery
Secondary Corneal endothelial cell density Measured by confocal or spectral microscopy 6 months after surgery
Secondary Corneal endothelial cell density Measured by confocal or spectral microscopy 2 years after surgery
Secondary Corneal endothelial cell density Measured by confocal or spectral microscopy 5 years after surgery
Secondary Patient reported outcome measure (PROMs) EuroQol-5 D (EQ-5D) questionnaire 6 months after surgery
Secondary Patient reported outcome measure (PROMs) EuroQol-5 D (EQ-5D) questionnaire 2 years after surgery
Secondary Patient reported outcome measure (PROMs) National Eye Institute Visual Function Questionnaire 25 (NEI-VFQ 25) 6 months after surgery
Secondary Patient reported outcome measure (PROMs) National Eye Institute Visual Function Questionnaire 25 (NEI-VFQ 25) 2 years after surgery
See also
  Status Clinical Trial Phase
Recruiting NCT06000865 - Glaucoma Rehabilitation With Action viDeo Games and Exercise - GRADE N/A
Recruiting NCT06278597 - Automatic Evaluation of the Anterior Chamber Angle Width by a New Non-contact Optical Device N/A
Active, not recruiting NCT04271709 - Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT) N/A
Recruiting NCT03274024 - The Asia Primary Tube Versus Trab (TVT) Study N/A
Completed NCT04552964 - Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of Glaucoma N/A
Recruiting NCT01957267 - Functional and Structural Imaging for Glaucoma
Active, not recruiting NCT04624698 - iStent Inject New Enrollment Post-Approval Study N/A
Completed NCT04020705 - The Efficacy of Citicoline in Eyedrops (OMK1) in Reducing the Progression of Glaucoma N/A
Completed NCT03150160 - Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma Phase 4
Not yet recruiting NCT05581498 - Glaucoma Exercise as Medicine Study (GEMS). N/A
Recruiting NCT02921568 - Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes N/A
Active, not recruiting NCT02901730 - Clinical Study of LPI With Different Laser Wavelengths N/A
Completed NCT02955849 - A Trial of China Laser and Surgery Study Glaucoma in Rural China Early Phase 1
Recruiting NCT02554214 - Pilot Clinical Trial on a New Adjustable Glaucoma Drainage Device N/A
Recruiting NCT02471105 - Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml Phase 4
Active, not recruiting NCT02390284 - Stop Retinal Ganglion Cell Dysfunction Study Phase 3
Completed NCT02653963 - Triamcinolone for Ahmed Glaucoma Valve N/A
Completed NCT02628223 - 180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma N/A
Completed NCT02246764 - Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension Phase 3
Completed NCT02520674 - Glaucoma Screening With Smartphone Ophthalmology N/A